HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA-Funded Study Spurs Consumer Reports’ Latest Lament On VMS Market Oversight

Executive Summary

Abstract of study notes methylsynephrine and isopropyloctopamine found in bitter orange supplements aren’t permitted by FDA as dietary ingredients. CR says despite the findings, FDA hasn't enforced against manufacturers or warned consumers.

You may also be interested in...



FDA's Latest Hornedine Find Is On Texas Firm’s Supplement Labels During Website Inspection

Hornedine isn’t an “old” dietary ingredient exempt from pre-market notification with proof its safety because it wasn’t available in the US food supply before October 1994. "T

Consumer Reports Has 'Concerns' About Echinacea, Turmeric Supplements

Nonprofit advocacy group says one third of echinacea and turmeric supplements it tested contained ingredients in amounts lower than labeled or elevated levels of lead or bacteria. Industry groups say CR used "arbitrary" standards based on preconceived, critical view of US supplement regulation.

FDA Debuts List For Rapidly Announcing Noncompliant Ingredients In Supplements

FDA announces addition of Dietary Supplement Ingredient Advisory List page to its website to identify ingredients it has preliminary determined should be used in dietary supplements. It also publishes warning letters submitted recently to firms marketing supplements containing two ingredients agency has concluded should not be used: eight were warned about using an ingredient identified as "DMHA" and three about using phenibut.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150173

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel